Biotron Ltd has released a press release.
BIT225 Reverses HIV-Induced Immune Evasion
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Biotron
- R&D Tax Refund Received
- BIT225 restores immune function in hiv-1 infections
- Biotron to Test its Compounds Against Coronavirus
- Biotron Secures $5.1 Million Underwriting Agreement
- Presentation to Investors
Later from Biotron
- Full Year Statutory Accounts
- Biotron Compounds Show Activity Against SARS-CoV-2 Virus
- Quarterly Cashflow Report
- Appendix 4C - quarterly
- $1.4M R&D Tax Rebate
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron